BidaskClub upgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a buy rating to a strong-buy rating in a research report report published on Wednesday.

VKTX has been the subject of several other research reports. HC Wainwright reissued a buy rating and issued a $7.00 price target on shares of Viking Therapeutics in a research report on Friday, November 10th. Roth Capital initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, November 21st. They issued a buy rating and a $5.00 price target for the company. Maxim Group set a $8.00 price target on shares of Viking Therapeutics and gave the company a buy rating in a research report on Tuesday, December 12th. Finally, ValuEngine cut shares of Viking Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $7.00.

Viking Therapeutics (NASDAQ VKTX) opened at $6.93 on Wednesday. Viking Therapeutics has a 1 year low of $0.88 and a 1 year high of $7.00. The company has a market cap of $271.03, a P/E ratio of -8.25 and a beta of 2.26.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). analysts anticipate that Viking Therapeutics will post -0.86 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new position in Viking Therapeutics in the 3rd quarter valued at approximately $108,000. Creative Planning boosted its position in Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 60,000 shares during the period. Virtu KCG Holdings LLC purchased a new position in Viking Therapeutics in the 2nd quarter valued at approximately $124,000. Victory Capital Management Inc. purchased a new position in Viking Therapeutics in the 4th quarter valued at approximately $791,000. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Viking Therapeutics during the 3rd quarter worth $554,000. 5.86% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Viking Therapeutics (VKTX) Upgraded to Strong-Buy at BidaskClub” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2018/02/08/viking-therapeutics-vktx-upgraded-to-strong-buy-at-bidaskclub.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.